Navigation Links
Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
Date:7/7/2008

- Company to Engage Contract Sales Organization And Seek New Marketing

Partner to Promote Product in UK -

LAVAL, QC, July 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has reacquired the sales and marketing rights to its once-daily tramadol product (Tradorec XL(R)) for the United Kingdom from Recordati Ireland Ltd. (Recordati). To promote its product in the UK, the Company will engage a contract sales organization and pursue a new licensing and distribution agreement with an appropriate marketing partner.

"Our once-daily tramadol product is achieving strong market penetration, particularly in Spain, Italy and Canada, and we believe that this success can be replicated in the UK with the appropriate sales and marketing effort behind Tradorec XL(R)," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "The market for tramadol products in the UK continues to exhibit strong growth and we are confident in both our product and its prospects in this market."

Under its agreement with Recordati to reacquire the UK rights to its once-daily tramadol product, Labopharm will continue to use the brand name Tradorec XL(R) in marketing its product. Labopharm will also receive a (euro)700,000 milestone from Recordati upon termination of Recordati's rights.

Labopharm is in discussions to finalize an agreement with a contract sales organization to promote Tradorec XL(R) in the UK. The Company is also in discussions to establish a licensing and distribution agreement with a new marketing partner.

The UK is the second largest European market for tramadol products (on a standard units basis) and one of the fastest growing of the five largest European markets for tramadol products (on a standard units basis). The UK tramadol market has experienced compound annual growth of 18% over the last five 12-month periods ended March 30.

About Labopharm In
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 On February 21st, the ... fabulous EcoLuxe Lounge, a day-long event that features a ... products and services. Organized by Debbie Durkin and Durkin ... placement producer, the EcoLuxe Lounge saw many notable attendees. ... on General Hospital, The Flash, Star Trek: Deep Space ...
(Date:3/3/2015)... CA (PRWEB) March 03, 2015 Findings ... , Researchers at UC Davis have developed and characterized ... cancer cells, causing them to self-destruct. This novel mechanism ... responsible for a usually fatal type of brain cancer ... cancers. , The article, to be published in ...
(Date:3/3/2015)... The Rheumatology Nurses Society (RNS) ... care and safe practice for patients with rheumatic diseases. ... biologic infusions are administered in an infusion center, provider’s ... registered nurse (RN), as defined in their State Nurse ... patients receiving these medications during a first infusion, as ...
(Date:3/3/2015)... TX (PRWEB) March 04, 2015 The ... information on the therapeutic development for Alopecia. Alopecia is ... are the two main types of alopecia. Causes for ... disorder. Symptoms of alopecia may include male pattern hair ... broken hair. Alopecia can be classified as focal or ...
(Date:3/3/2015)... March 03, 2015 Daylight Savings Time may ... Kothare, MD, has tips for parents. , Parents and their ... at 2:00 a.m. when they set their clocks forward one ... up that day -- one hour earlier -- you will ... parents should start thinking about “sleep hygiene” for their kids ...
Breaking Medicine News(10 mins):Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2
... Researchers at The Wistar Institute announce the discovery of ... with human papillomavirus (HPV). Their results, in both ... inhibitors protect a tumor-suppressing protein targeted by viral proteins, ... scientists presented their findings in the April 20 issue ...
... are testing whether different doses of an established blood pressure ... in people with mild hypertension, possibly with fewer side effects ... funded with a $1.9 million grant from the National Heart ... in the United States. The study drug, carvedilol ...
... April 26 (HealthDay News) -- The fourth National Prescription Drug ... 2 p.m., the U.S. Drug Enforcement Administration says. The ... and unused prescription drugs. At the third Take-Back Day ... tons) of unwanted or expired medications at more than 5,300 ...
... WEDNESDAY, April 25 (HealthDay News) -- Urban areas contaminated decades ... of aggravated assault, according to a new study. The ... dust emitted from older vehicles that ran on leaded gasoline, ... paint could have played a role as well. ...
... rs1051730-rs16969968 genotype and objective measures of tobacco exposure, which ... entirely, mediated by level of tobacco exposure, according to ... of the National Cancer Institute . The rs1051730-rs16969968 ... smoking, lung cancer risk, and other smoking-related outcomes. Prior ...
... are proposing a new model of care collaboration ... with various emergent cardiovascular conditions which require rapid, ... mortality, in an article published April 24 in ... ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina, out-of-hospital ...
Cached Medicine News:Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:URMC clinical trial tests new regimen for hypertension 2Health News:Leaded Gas Exposure Linked to Later Violence: Study 2Health News:Genetic variants, tobacco exposure and lung cancer risk 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2
(Date:3/3/2015)... March 3, 2015  American Biosurgical, LLC ("ABI") ... cable manufacturer actively engaged in the design, development ... the world,s leading medical device companies has announced ... low volume custom medical cable manufacturer based in ... MTI brand under the name MTI Medical Cables.  ...
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... - Sante Medical Hair Restoration is now offering the ... The ARTAS Robotic System is a state-of-the-art ... for transplantation. This latest development in minimally-invasive hair ... linear scar. "The ARTAS technology extends ... surgery." says Dr. Louis Grondin , Medical ...
Breaking Medicine Technology:American Biosurgical Acquires MTI Corporation 2No linear scar. Permanent results. 2
... Children,s Oncology Group Report Shows the Addition of ... of Death by 30% in Osteosarcoma Patients, ... IDMI ) today announced the Journal of ... 3 mifamurtide (L-MTP-PE) clinical trial,(INT-0133), entitled "Osteosarcoma: The ...
... Show Subjects Receiving,Infrequently Administered Ustekinumab Maintained Improvement from Psoriasis ... ... SAN ANTONIO, Feb. 2 One-year data from a second,double-blind, ... weeks provided sustained, clinically meaningful,improvement in the treatment of moderate ...
Cached Medicine Technology:IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 3IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 4IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 5IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 6IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 7Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 2Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 3Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 4Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 5
... low cost, low volume alternative. Whole blood is ... separated from whole blood by centrifugation in a ... the Cebus single use cartridge. The cartridge is ... activate the concentrating process. Finally, the cartridge is ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
... device restores lordosis and ... less reaming of the ... Danek's Tapered Laparoscopic Instruments ... and reproducibly place the ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Medicine Products: